La Lettre report of AstraZeneca exclusivity fueled premarket surge.
French financial newsletter La Lettre reported on March 12 that Abivax granted AstraZeneca exclusive access to confidential data until March 23 to formalize a takeover offer, after which the company could negotiate with others. This reignited ongoing M&A speculation, building on prior rumors involving AstraZeneca and Eli Lilly earlier in 2026 that had previously driven sharp gains. Financial outlets like Boursier.com noted the stock flaming on these developments, with social media amplifying trader interest amid high premarket volume. The 12.34% rise reflects biotech sector sensitivity to acquisition chatter ahead of upcoming catalysts like Q4 earnings on March 23.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.